In which cancers do doctors use lurbinectedin again (readministration)?
Readministration of lurbinectedin is considered when a patient has previously benefited from the drug and can be re-treated after a period off therapy. The provided information does not specify which tumor types require (or most commonly use) lurbinectedin readministration.
Does readministration depend on a specific biomarker or trial population?
The need for readministration can depend on how a study defined “re-treatment” (for example, requiring prior response or a minimum time since last dose), and on the inclusion criteria for the specific tumor cohort. However, the information available here does not list tumor types, biomarkers, or trial settings tied to readministration.
Which practical answer can be given without tumor-type details?
If your goal is to identify the tumor types where readministration is explicitly described, the missing piece is the protocol/label/trial document that states “readministration” and then ties it to particular malignancies. Share the source text (trial name, protocol section, or label wording) and I can map it to the tumor types it applies to.
If you meant “when is it needed because of resistance/progression?”
In many oncology settings, re-dosing after prior benefit is used when clinicians believe the drug may still work again (for example, after a treatment-free interval), but that concept is not tumor-type specific on its own. The exact tumor types where this is recommended or required must come from the specific prescribing information or study protocol.
Next step
Paste the excerpt you’re working from (or tell me the trial/indication name), and I’ll extract the exact tumor types where lurbinectedin readministration is stated to be necessary.